Hexachlorobenzene (HCB), as one of the persistent organic pollutants (POPs) and possible human carcinogens, particularly resistant to biodegradation. In this study, HcbA1A3, a different flavin-N5-peroxide using enzymes and the only known naturally aerobic dechlorinase HCB, the biochemical marked.
Its clear preference for HCB in the binding affinity of sets that can only oxidize HcbA1 HCB than less chlorinated benzene as pentachlorobenzene and tetrachlorobenzenes. In addition, the crystal structure and complex HcbA1 with FMN resolved, revealing HcbA1 as new members of the bacterial luciferase-like family. Compared with a close homolog, the substrate binding pocket is much smaller than HcbA1 show limited space requirements for catalysis.
In the midst of an active, Tyr362 and Asp315 necessary in maintaining a normal conformation HcbA1, while Arg311, Arg314, Phe10, Val59 and Met12 is important for substrate affinity. They should have a place in the productive orientation HCB through multiple interactions. His17, with close contact with the oxidation locations HCB, possibly targeting the improvement of chlorine atoms and stabilizing the reaction intermediates.
Enzymatic characteristics and crystal structures reported here provide new insights into the substrate specificity and catalytic mechanism HcbA1, which opens the way for rational engineering and applications in bioremediation of polluted HCB environments.IMPORTANCE As an endocrine disruptor and possible carcinogen to humans, hexachlorobenzene (HCB) is resistant to biodegradation, largely due to difficulties in dechlorination.
Lack of knowledge to dechlorinases HCB limit their application in bioremediation. More recently, a HcbA1A3 monooxygenases reported HCB, which is the only known naturally aerobic HCB dechlorinase so far. Here we report the biochemical and structural characterization, which provides new insight into the substrate selectivity and catalytic mechanism. The study also improve our understanding of dechlorinases HCB and flavin-N5-peroxide using enzymes.
Ensuring the biochemical function of pectin methylesterase important in microbial gut Bacteroides thetaiotaomicron
Pectin is a major food source of nutrients for the human intestinal microbiota (HGM). Bacteroides thetaiotaomicron protruding gut microbes was recently shown to encode a founding member of (BT1017) of a new family of pectin methylesterases (PMEs) important for the metabolism of pectin complex rhamnogalacturonan-II (RG-II).
However, the biochemical and structural knowledge of this family less. Here, we show that the BT1017 is very important for the metabolism of a ΔBT1017oligoB oligosaccharides derived RG-II produced by BT1017 deletion mutant (ΔBT1017) during growth on carbohydrate extract of apple juice.
ΔBT1017oligoB structural analysis using a combination of enzymatic, mass spectrometry and nuclear magnetic resonance approach to reveal that it was a lady-oligosaccharides bi-methylated GlcA-β1,4- (2-O-Me-Xyl-α1,3) -Fuc- α1,4- (gALA-β1,3) -Rha-α1,3-Fire-β1,2- (Araf-α1,3) – (gala-α1,4) -GalA component containing RG-II backbones and side chains. We show that the catalytic module BT1017 adopt an alpha / beta (α / β) hydrolase fold, which consists of 10 twisted β-sheet strand middle sandwiched by multiple α-helices. It is a new fold for PMEs, which is dominated by left-handed β-helix proteins.
Bioinformatics analysis revealed that the family is dominated by a sequence of genera protruding from HGM, including Bacteroides and Prevotella Our results not only highlight the important role played by this family of enzymes in the metabolism of pectin but give new insights into the molecular basis of adaptation B. thetaiotaomicron to gut human.
Cellular and biochemical mechanisms of meroterpenoid Oncocalyxone antileukemic A
Oncocalyxone A, 1,4-benzokuinon derived from Cordia oncocalyx, showed anti-inflammatory, antimicrobial and anti-diabetic. The purpose of this study was to (1) examine the cytotoxic action oncocalyxone A on normal and tumor cell lines of human and (2) determine the mechanistic action effects on leukemia cells using the technique of the underlying cellular and molecular.
Antiproliferative studies on cancer cell lines, cells of peripheral blood mononuclear cells, and human erythrocytes done using colorimetric tests. To understand cytotoxicity, an assessment carried out by the HL-60 leukemia cells (8, 16.5, or 33 M) after 24 h incubation by using light and fluorescence microscopy, trypan blue, cytometry, Comet assay, western blot caspases and poly-ADP- flow ribose polymerase (PARP), and the effect on topoisomerase I and II. A Oncocalyxone exhibited cytotoxic action in HL-60 cells and dividing leukocytes, but minimal hemolytic action on erythrocytes.
The mechanistic investigation showed a decrease in cell viability, loss of membrane integrity, cells shrink, chromatin condensation, blebbings, phosphatidylserine externalization, caspase activation, PARP cleavage, mitochondrial depolarization and DNA damage. Pre-treatment with N-acetylcysteine 4 mM significantly reduced DNA damage and prevent the loss of membrane integrity. Oncocalyxone A free radical activity depends shown antileukemic through apoptosis and DNA damage induced in HL-60 cells.
Oncocalyxone A has a chemical structural simplicity allows it to be a cost-effective alternative. These properties justify further improvements to improve the activity and selectivity and pharmaceutical formulation development. Abbreviations Acridine orange, AO; ANOVA, analysis of variance; BSA, bovine serum albumin; IN, Damage Index; DMSO, Dimethylsulfoxide; EC50, the effective concentration of 50%; EDTA, ethylenediamine tetraacetic acid; EB, ethidium bromide; HCT-116, colon carcinoma lines; HL-60, promyelocytic leukemia line; IC50, 50% inhibitory concentration; MTT, 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H-tetrazolium bromide; OVCAR-8 ovarian carcinoma line; NAC, N-acetylcysteine, PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PI, propidium iodide; PARP, poly-ADP-ribose polymerase; RPMI-1640 media Roswell Park Memorial Institute; SF-295 glioblastoma line; ROS, reactive oxygen species; 7-AAD, 7-amino-aktinomisin D; H2-DCF-DA, 7′-dichlorodihydrofluorescein diacetate.
Biochemistry and in silico identification of the active site and catalytic mechanisms of circadian HESPERIN deadenylase
24h a molecular clock based on the stability of the transcript rhythmic disclosed. Shortening of the poly (A) tail of the mRNA is often the first step and the rate-limiting determine the life span of mRNA and catalyzed by deadenylases.
Here, we determine the catalytic site Hesperin, a circadian deadenylase recently described in plants, using a modified site-directed mutagenesis protocols and custom vectors, pATHRA. To explore the catalytic efficiency of AtHESPERIN we examined the effect of AMP and neomycin, and used molecular modeling simulations to propose a catalytic mechanism.
Collectively, biochemistry and classify AtHESPERIN silico results in EEP deadenylase superfamily and contribute to the understanding of the complex mechanisms of circadian mRNA turnover.
ALOX5 Antibody |
|||
E315047 | EnoGene | 100ug/200ul | EUR 295 |
Description: Available in various conjugation types. |
ALOX5 Antibody |
|||
CAC08226-100ug | Biomatik Corporation | 100ug | EUR 314 |
ALOX5 Antibody |
|||
CAC08226-50ug | Biomatik Corporation | 50ug | EUR 199.2 |
ALOX5 antibody |
|||
70R-14181 | Fitzgerald | 100 ug | EUR 519 |
Description: Affinity purified Rabbit polyclonal ALOX5 antibody |
ALOX5 antibody |
|||
70R-15688 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal ALOX5 antibody |
ALOX5 antibody |
|||
70R-33363 | Fitzgerald | 100 ug | EUR 294 |
Description: Rabbit polyclonal ALOX5 antibody |
ALOX5 Antibody |
|||
1-CSB-PA008474 | Cusabio |
|
|
Description: A polyclonal antibody against ALOX5. Recognizes ALOX5 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/10000 |
ALOX5 Antibody |
|||
1-CSB-PA043268 | Cusabio |
|
|
Description: A polyclonal antibody against ALOX5. Recognizes ALOX5 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:500-1:5000, IHC:1:50-1:150 |
ALOX5 Antibody |
|||
1-CSB-PA001624GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against ALOX5. Recognizes ALOX5 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IF |
ALOX5 Antibody |
|||
1-CSB-PA001624LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against ALOX5. Recognizes ALOX5 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
ALOX5 Antibody |
|||
ABD6881 | Nova Lifetech | 100ug | EUR 325 |
ALOX5 Antibody |
|||
MBS7136531-005mL | MyBiosource | 0.05mL | EUR 220 |
ALOX5 Antibody |
|||
MBS7136531-01mL | MyBiosource | 0.1mL | EUR 300 |
ALOX5 Antibody |
|||
MBS7136531-5x01mL | MyBiosource | 5x0.1mL | EUR 1350 |
ALOX5 Antibody |
|||
MBS7006095-005mg | MyBiosource | 0.05mg | EUR 190 |
ALOX5 Antibody |
|||
MBS7006095-01mg | MyBiosource | 0.1mg | EUR 270 |
ALOX5 Antibody |
|||
MBS7006095-5x01mg | MyBiosource | 5x0.1mg | EUR 1205 |
ALOX5 Antibody |
|||
MBS7119279-005mg | MyBiosource | 0.05mg | EUR 150 |
ALOX5 Antibody |
|||
MBS7119279-01mg | MyBiosource | 0.1mg | EUR 190 |
ALOX5 Antibody |
|||
MBS7119279-5x01mg | MyBiosource | 5x0.1mg | EUR 845 |
ALOX5 Antibody |
|||
MBS7123106-005mL | MyBiosource | 0.05mL | EUR 190 |
ALOX5 Antibody |
|||
MBS7123106-01mL | MyBiosource | 0.1mL | EUR 270 |
ALOX5 Antibody |
|||
MBS7123106-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
ALOX5 Antibody |
|||
MBS7123107-005mL | MyBiosource | 0.05mL | EUR 190 |
ALOX5 Antibody |
|||
MBS7123107-01mL | MyBiosource | 0.1mL | EUR 270 |
ALOX5 Antibody |
|||
MBS7123107-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
ALOX5 Antibody |
|||
MBS9404993-01mL | MyBiosource | 0.1mL | EUR 305 |
ALOX5 Antibody |
|||
MBS9404993-5x01mL | MyBiosource | 5x0.1mL | EUR 1230 |
ALOX5 antibody |
|||
MBS9409656-005mL | MyBiosource | 0.05mL | EUR 300 |
ALOX5 antibody |
|||
MBS9409656-01mL | MyBiosource | 0.1mL | EUR 390 |
ALOX5 antibody |
|||
MBS9409656-5x01mL | MyBiosource | 5x0.1mL | EUR 1610 |
ALOX5 Antibody |
|||
MBS8505300-01mL | MyBiosource | 0.1mL | EUR 325 |
ALOX5 Antibody |
|||
MBS8505300-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
ALOX5 Antibody |
|||
MBS8505300-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
ALOX5 Antibody |
|||
MBS8505300-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
ALOX5 Antibody |
|||
MBS8505300-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
ALOX5 Antibody |
|||
MBS8516351-01mg | MyBiosource | 0.1mg | EUR 305 |
ALOX5 Antibody |
|||
MBS8516351-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
ALOX5 Antibody |
|||
MBS8516351-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
ALOX5 Antibody |
|||
MBS8516351-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
ALOX5 Antibody |
|||
MBS8516351-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
ALOX5 Antibody |
|||
MBS2529689-006mL | MyBiosource | 0.06mL | EUR 230 |
ALOX5 Antibody |
|||
MBS2529689-012mL | MyBiosource | 0.12mL | EUR 310 |
ALOX5 Antibody |
|||
MBS5312940-01mg | MyBiosource | 0.1mg | EUR 975 |
ALOX5 Antibody |
|||
MBS5312940-5x01mg | MyBiosource | 5x0.1mg | EUR 4245 |
ALOX5 Antibody |
|||
MBS9607534-01mL | MyBiosource | 0.1mL | EUR 260 |
ALOX5 Antibody |
|||
MBS9607534-02mL | MyBiosource | 0.2mL | EUR 305 |
ALOX5 Antibody |
|||
MBS9607534-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
ALOX5 antibody (Ser523) |
|||
70R-14936 | Fitzgerald | 100 ul | EUR 497 |
Description: Rabbit polyclonal ALOX5 antibody (Ser523) |
ALOX5 antibody (Ser271) |
|||
70R-33362 | Fitzgerald | 100 ug | EUR 294 |
Description: Rabbit polyclonal ALOX5 antibody (Ser271) |
ALOX5 antibody (Ser523) |
|||
70R-34631 | Fitzgerald | 100 ug | EUR 294 |
Description: Purified Rabbit polyclonal ALOX5 antibody (Ser523) |
ALOX5 antibody (Ser523) |
|||
MBS835508-01mL | MyBiosource | 0.1mL | EUR 800 |
ALOX5 antibody (Ser523) |
|||
MBS835508-5x01mL | MyBiosource | 5x0.1mL | EUR 3440 |
ALOX5 (pS271) Antibody |
|||
20-abx123322 | Abbexa |
|
|
ALOX5 (pS663) Antibody |
|||
abx148138-100ug | Abbexa | 100 ug | EUR 526.8 |
ALOX5 (pS523) Antibody |
|||
abx012014-100ug | Abbexa | 100 ug | EUR 526.8 |
ALOX5 (pS271) Antibody |
|||
abx123322-100l | Abbexa | 100 µl | EUR 200 |
ALOX5 (pS271) Antibody |
|||
abx123322-1ml | Abbexa | 1 ml | EUR 475 |
ALOX5 (pS271) Antibody |
|||
abx123322-200l | Abbexa | 200 µl | EUR 325 |
ALOX5 Polyclonal Antibody |
|||
A58062 | EpiGentek |
|
|
ALOX5 Conjugated Antibody |
|||
C35564 | SAB | 100ul | EUR 476.4 |
ALOX5 Polyclonal Antibody |
|||
E-AB-10040-120uL | Elabscience Biotech | 120uL | EUR 240 |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
E-AB-10040-200uL | Elabscience Biotech | 200uL | EUR 399 |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
E-AB-10040-20uL | Elabscience Biotech | 20uL | EUR 73 |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
E-AB-10040-60uL | Elabscience Biotech | 60uL | EUR 143 |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
MBS128009-002mL | MyBiosource | 0.02mL | EUR 200 |
ALOX5 Polyclonal Antibody |
|||
MBS128009-005mL | MyBiosource | 0.05mL | EUR 255 |
ALOX5 Polyclonal Antibody |
|||
MBS128009-01mL | MyBiosource | 0.1mL | EUR 345 |
ALOX5 Polyclonal Antibody |
|||
MBS128009-02mL | MyBiosource | 0.2mL | EUR 545 |
ALOX5 Polyclonal Antibody |
|||
MBS128009-5x02mL | MyBiosource | 5x0.2mL | EUR 2265 |
ALOX5 Polyclonal Antibody |
|||
A71901 | EpiGentek | 50 μl | EUR 408 |
ALOX5 Polyclonal Antibody |
|||
E-AB-67417-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
E-AB-67417-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
E-AB-67417-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
E-AB-67417-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
ALOX5 Polyclonal Antibody |
|||
MBS2566249-006mL | MyBiosource | 0.06mL | EUR 190 |
ALOX5 Polyclonal Antibody |
|||
MBS2566249-012mL | MyBiosource | 0.12mL | EUR 265 |
ALOX5 Polyclonal Antibody |
|||
MBS2566249-02mL | MyBiosource | 0.2mL | EUR 415 |
ALOX5 Polyclonal Antibody |
|||
MBS2566249-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
ALOX5 Polyclonal Antibody |
|||
MBS2522401-002mL | MyBiosource | 0.02mL | EUR 140 |
ALOX5 Polyclonal Antibody |
|||
MBS2522401-006mL | MyBiosource | 0.06mL | EUR 180 |
ALOX5 Polyclonal Antibody |
|||
MBS2522401-012mL | MyBiosource | 0.12mL | EUR 260 |
ALOX5 Polyclonal Antibody |
|||
MBS2522401-02mL | MyBiosource | 0.2mL | EUR 405 |
ALOX5 Polyclonal Antibody |
|||
MBS2524895-002mL | MyBiosource | 0.02mL | EUR 135 |
ALOX5 Polyclonal Antibody |
|||
MBS2524895-006mL | MyBiosource | 0.06mL | EUR 190 |
ALOX5 Polyclonal Antibody |
|||
MBS2524895-012mL | MyBiosource | 0.12mL | EUR 265 |
ALOX5 Polyclonal Antibody |
|||
MBS2524895-02mL | MyBiosource | 0.2mL | EUR 415 |
ALOX5 Polyclonal Antibody |
|||
MBS2524895-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
ALOX5 Conjugated Antibody |
|||
MBS9446036-01mLAF350 | MyBiosource | 0.1mL(AF350) | EUR 480 |
ALOX5 Conjugated Antibody |
|||
MBS9446036-01mLAF405 | MyBiosource | 0.1mL(AF405) | EUR 480 |
ALOX5 Conjugated Antibody |
|||
MBS9446036-01mLAF488 | MyBiosource | 0.1mL(AF488) | EUR 480 |
ALOX5 Conjugated Antibody |
|||
MBS9446036-01mLAF555 | MyBiosource | 0.1mL(AF555) | EUR 480 |
ALOX5 Conjugated Antibody |
|||
MBS9446036-01mLBiotin | MyBiosource | 0.1mL(Biotin) | EUR 480 |
ALOX5 Polyclonal Antibody |
|||
RD267417A-120uL | Reddot Biotech | 120μL | EUR 360 |
Description: This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
ALOX5 Polyclonal Antibody |
|||
RD267417A-200uL | Reddot Biotech | 200μL | EUR 630 |
Description: This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
ALOX5 Polyclonal Antibody |
|||
RD267417A-60uL | Reddot Biotech | 60μL | EUR 204 |
Description: This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
ALOX5 Polyclonal Antibody |
|||
RD75005A-120uL | Reddot Biotech | 120μL | EUR 360 |
Description: This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
ALOX5 Polyclonal Antibody |
|||
RD75005A-200uL | Reddot Biotech | 200μL | EUR 630 |
Description: This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
ALOX5 Polyclonal Antibody |
|||
RD75005A-20uL | Reddot Biotech | 20μL | EUR 109.5 |
Description: This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
ALOX5 Polyclonal Antibody |
|||
RD75005A-60uL | Reddot Biotech | 60μL | EUR 214.5 |
Description: This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
ALOX5 Antibody - middle region |
|||
MBS3222309-01mL | MyBiosource | 0.1mL | EUR 455 |
ALOX5 Antibody - middle region |
|||
MBS3222309-5x01mL | MyBiosource | 5x0.1mL | EUR 1995 |
ALOX5 Antibody, HRP conjugated |
|||
1-CSB-PA001624LB01HU | Cusabio |
|
|
Description: A polyclonal antibody against ALOX5. Recognizes ALOX5 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
ALOX5 Antibody, HRP conjugated |
|||
MBS1499651-005mg | MyBiosource | 0.05mg | EUR 190 |
ALOX5 Antibody, HRP conjugated |
|||
MBS1499651-01mg | MyBiosource | 0.1mg | EUR 270 |
ALOX5 Antibody, HRP conjugated |
|||
MBS1499651-5x01mg | MyBiosource | 5x0.1mg | EUR 1205 |
ALOX5 Antibody, FITC conjugated |
|||
1-CSB-PA001624LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against ALOX5. Recognizes ALOX5 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
ALOX5 Antibody, FITC conjugated |
|||
MBS1499096-005mg | MyBiosource | 0.05mg | EUR 190 |
ALOX5 Antibody, FITC conjugated |
|||
MBS1499096-01mg | MyBiosource | 0.1mg | EUR 270 |
ALOX5 Antibody, FITC conjugated |
|||
MBS1499096-5x01mg | MyBiosource | 5x0.1mg | EUR 1205 |
OACA02570-50UG - ALOX5 Antibody |
|||
OACA02570-50UG | Aviva Systems Biology | 50ug | EUR 179 |
ALOX5 Antibody, Biotin conjugated |
|||
1-CSB-PA001624LD01HU | Cusabio |
|
|
Description: A polyclonal antibody against ALOX5. Recognizes ALOX5 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
OAEB01837-100UG - ALOX5 Antibody |
|||
OAEB01837-100UG | Aviva Systems Biology | 100ug | EUR 349 |
OACA02570-100UG - ALOX5 Antibody |
|||
OACA02570-100UG | Aviva Systems Biology | 100ug | EUR 319 |
ALOX5 Antibody, Biotin conjugated |
|||
MBS1493680-005mg | MyBiosource | 0.05mg | EUR 190 |
ALOX5 Antibody, Biotin conjugated |
|||
MBS1493680-01mg | MyBiosource | 0.1mg | EUR 270 |
ALOX5 Antibody, Biotin conjugated |
|||
MBS1493680-5x01mg | MyBiosource | 5x0.1mg | EUR 1205 |
Phospho- ALOX5 (Ser523) Antibody |
|||
ABF0064 | Nova Lifetech | 100ug | EUR 325 |
ALOX5 (Phospho- Ser663) Antibody |
|||
ABF8359 | Nova Lifetech | 100ug | EUR 325 |
ALOX5 (Phospho-Ser663) Antibody |
|||
12671-100ul | SAB | 100ul | EUR 302.4 |
ALOX5 (Phospho-Ser663) Antibody |
|||
12671-50ul | SAB | 50ul | EUR 224.4 |
ALOX5 (Phospho-Ser523) Antibody |
|||
12128 | SAB | 100ul | EUR 319 |
ALOX5 (Phospho-Ser523) Antibody |
|||
12128-100ul | SAB | 100ul | EUR 302.4 |
ALOX5 (Phospho-Ser523) Antibody |
|||
12128-50ul | SAB | 50ul | EUR 224.4 |
ALOX5 (Phospho-Ser523) Antibody |
|||
E11-8487A | EnoGene | 100μg | EUR 225 |
Description: Available in various conjugation types. |
ALOX5 (Phospho-Ser523) Antibody |
|||
E012128 | EnoGene | 100μg/100μl | EUR 255 |
Description: Available in various conjugation types. |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS9404495-005mL | MyBiosource | 0.05mL | EUR 245 |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS9404495-01mL | MyBiosource | 0.1mL | EUR 305 |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS9404495-5x01mL | MyBiosource | 5x0.1mL | EUR 1230 |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS858202-01mg | MyBiosource | 0.1mg | EUR 305 |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS858202-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS858202-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS858202-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
ALOX5 (Phospho-Ser523) Antibody |
|||
MBS858202-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
ALOX5 (Phospho-Ser663) Antibody |
|||
MBS9416759-005mL | MyBiosource | 0.05mL | EUR 245 |
ALOX5 (Phospho-Ser663) Antibody |
|||
MBS9416759-01mL | MyBiosource | 0.1mL | EUR 305 |